In collaboration with the Institute Antiviral Research at Utah State, Gnubiotics has accelerated pre-clinical trials to explore the effects of its multivalent glycan formulations on live SARS-CoV-2 viruses in cell culture as well as evaluating the inhibition of viral- induced cytopathic effects (CPE).

Targeting glycan receptors present on the SARS-CoV-2 cell surface may be critical to viral binding and is a novel approach under consideration for inhibition of SARS-CoV-2 viral entry and adsorption into target host cells.

Early data has shown sialylated glycans may have an effect on a range of virus including the influenza virus. Gnubiotics remains optimistic that we can be part of the global solution and response to stop the COVID-19 pandemic.

Download press release here.

Author

Logotipo GNU Biotics

Published by Gnubiotics Sciences

Since 2016, Gnubiotics has been working to solve microbiome-related health conditions by applying our understanding of nature’s principles.

For more information

Fill in the form and our team will get back to you.